|
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
RECRUITINGPhase 3Sponsored by Novo Nordisk A/S
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-08-31
Est. completion2028-06-27
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations41 sites
View on ClinicalTrials.gov →
NCT07720271
Summary
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Male or female (sex at birth). * Age 18 and older (both inclusive) at time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Conditions3
ObesityOverweightWeight Loss
Interventions1
Locations41 sites
Pinnacle Research Group LLC
Univ of Alabama Birmingham
Chambliss Clinical Trials LLC
Providence Medical Foundation
Torrance Clinical Research Institute, Inc.
Find trials near these locations
Weight Loss trials in JacksonvilleWeight Loss trials in OrlandoWeight Loss trials in ChicagoWeight Loss trials in IndianapolisWeight Loss trials in Las VegasWeight Loss trials in New YorkWeight Loss trials in RaleighWeight Loss trials in DallasAll trials in AlabamaAll trials in CaliforniaAll trials in ColoradoAll trials in FloridaAll trials in GeorgiaAll trials in HawaiiAll trials in IllinoisAll trials in IndianaAll trials in MichiganAll trials in MissouriAll trials in NevadaAll trials in New YorkAll trials in North CarolinaAll trials in OklahomaAll trials in Rhode IslandAll trials in South CarolinaAll trials in TexasAll trials in Virginia
Related trials
- AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications — Novo Nordisk A/S
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication — Novo Nordisk A/S
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication — Novo Nordisk A/S
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide — Novo Nordisk A/S
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Started2026-08-31
Est. completion2028-06-27
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations41 sites
View on ClinicalTrials.gov →
NCT07720271